187 related articles for article (PubMed ID: 27287481)
1. Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity.
Martin J; Arm J; Smart J; Palazzi K; Capp A; Ainsworth P; Cowin G
Eur Radiol; 2017 Mar; 27(3):995-1003. PubMed ID: 27287481
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of vertebral marrow adipose tissue in postmenopausal female using MRI chemical shift-based water-fat separation.
Li GW; Xu Z; Chen QW; Tian YN; Wang XY; Zhou L; Chang SX
Clin Radiol; 2014 Mar; 69(3):254-62. PubMed ID: 24286935
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
[TBL] [Abstract][Full Text] [Related]
6. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
7. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.
Greenspan SL; Wagner J; Nelson JB; Perera S; Britton C; Resnick NM
J Bone Miner Res; 2013 Feb; 28(2):325-32. PubMed ID: 22991066
[TBL] [Abstract][Full Text] [Related]
8. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
9. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
10. Percentage fat fraction in magnetic resonance imaging: upgrading the osteoporosis-detecting parameter.
Chang R; Ma X; Jiang Y; Huang D; Chen X; Zhang M; Hao D
BMC Med Imaging; 2020 Mar; 20(1):30. PubMed ID: 32183731
[TBL] [Abstract][Full Text] [Related]
11. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
Deng J; Li W; Yang L; Wang L; Zou D
Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
13. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
14. Assessment and predictors of fatigue in men with prostate cancer receiving radiotherapy and androgen deprivation therapy.
Bandara V; Capp A; Ahmed G; Arm J; Martin J
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):683-690. PubMed ID: 31588674
[TBL] [Abstract][Full Text] [Related]
15. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
17. Vertebral bone marrow fat content in normal adults with varying bone densities at 3T magnetic resonance imaging.
He J; Fang H; Li X
Acta Radiol; 2019 Apr; 60(4):509-515. PubMed ID: 30130978
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy.
Ziaran S; Goncalves FM; Breza JS
Endocr Regul; 2011 Oct; 45(4):199-204. PubMed ID: 22073949
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Estimation of the Fat Fraction and R₂
Kim D; Kim SK; Lee SJ; Choo HJ; Park JW; Kim KY
Korean J Radiol; 2019 Jun; 20(6):916-930. PubMed ID: 31132817
[TBL] [Abstract][Full Text] [Related]
20. Rapid determination of vertebral fat fraction over a large range of vertebral bodies.
Martin J; Nicholson G; Cowin G; Ilente C; Wong W; Kennedy D
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):155-63. PubMed ID: 24373427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
